Research programme: recombinant human fibrinogen - The Medicines Company

Drug Profile

Research programme: recombinant human fibrinogen - The Medicines Company

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProFibrix
  • Developer The Medicines Company
  • Class Acute-phase proteins; Blood coagulation factors; Proteins
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Blood coagulation disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Coagulation-disorders in Netherlands (Parenteral, Injection)
  • 05 Aug 2013 ProFibrix has been acquired by The Medicines Company
  • 20 Jun 2011 Preclinical trials in Coagulation disorders in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top